Cargando…

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, Kamdar, Manali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646768/ https://www.ncbi.nlm.nih.gov/pubmed/36542826 http://dx.doi.org/10.1182/blood.2022018730

Ejemplares similares

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2022)

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel
por: Olson, N. Eric, et al.
Publicado: (2023)

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2022)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
por: Rasheed, Yusuf, et al.
Publicado: (2023)

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
por: Thieblemont, Catherine, et al.
Publicado: (2023)

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial
por: Burmeister Getz, E, et al.
Publicado: (2016)

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
por: Shouse, Geoffrey, et al.
Publicado: (2023)

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
por: Jacobson, Caron A., et al.
Publicado: (2023)

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
por: Zeidan, Amer M., et al.
Publicado: (2022)

Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
por: Elliott, Daisy, et al.
Publicado: (2018)

Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
por: Tan, Wei Shen, et al.
Publicado: (2020)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

In‐hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial
por: Müllhaupt, Gautier, et al.
Publicado: (2019)

Ultra‐hypofractionated radiation therapy for unfavourable intermediate‐risk and high‐risk prostate cancer is safe and effective: 5‐year outcomes of a phase II trial
por: Macias, Victor A., et al.
Publicado: (2019)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
por: Dawson, Mark A., et al.
Publicado: (2023)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
por: Anders, Carey, et al.
Publicado: (2014)

Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial
por: Koch, Giacomo, et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022)

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
por: Scordo, Michael, et al.
Publicado: (2023)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kiftc2790uiuflep4hd5c0nhgm